
Cys-TAT(47-57)
CAS No. 583836-55-9
Cys-TAT(47-57)( Cys-[HIV-Tat (47-57)] )
Catalog No. M29884 CAS No. 583836-55-9
Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCys-TAT(47-57)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
-
DescriptionCys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.This peptide corresponds to the protein transduction domain of the TAT protein.
-
In Vitro——
-
In Vivo——
-
SynonymsCys-[HIV-Tat (47-57)]
-
PathwayMicrobiology/Virology
-
TargetHIV
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number583836-55-9
-
Formula Weight1661.99
-
Molecular FormulaC67H124N34O14S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Cys}{Tyr}{Gly}{Arg}{Lys}{Lys}{Arg}{Arg}{Gln}{Arg}{Arg}{Arg}-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Bertrand SJ, et al. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol. 2013 Oct;248:228-35.
molnova catalog



related products
-
BNM-III-170 trifluor...
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
-
YIR-819 TFA salt
YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).
-
ST7612AA1
ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo.